Company
Our mission is to create real hopes
through innovative new drug developments
through innovative new drug developments
About the Company
- HOME
- Company
- About the Company

Pinotbio has been conducting R&D
on best-in-class targeted anticancer
therapies for relapsed/
refractory cancer, ADC platform,
and treatment for ischemic
ophthalmic disease.
Our pipeline consists of NTX-301, a targeted anticancer therapy for blood cancer/solid cancer, a next-generation ADC anticancer drug candidate and platform technology PINOT-ADC™, and NTX-101, an eye drop treatment for ischemic optic neuropathy.
-
Next-Gen Targeted
Anticancer TherapyClinical safety and efficacy has been confirmed for NTX-301
Dual action, exerting powerful anticancer effect
ADC PlatformNext Generation ADC Platform Technology
Payload and Linker that can overcome resistance
-
Biotech Specializing
in Oncology TreatmentInnovative therapy for relapsed/refractory disease
Operating a global clinical development network
-
Global Leading Biotech for Novel Anticancer Treatment